Is Abpro Holdings, Inc. (ABPO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1124.0% / 30% | 962.6% / 30% | 109.1% / 30% | 4.92% / 5% | ✗ NOT HALAL |
| DJIM | 1124.0% / 33% | 962.6% / 33% | 109.1% / 33% | 4.92% / 5% | ✗ NOT HALAL |
| MSCI | 71.4% / 33% | 61.1% / 33% | 6.9% / 33% | 4.92% / 5% | ✗ NOT HALAL |
| S&P | 1124.0% / 33% | 962.6% / 33% | 109.1% / 33% | 4.92% / 5% | ✗ NOT HALAL |
| FTSE | 71.4% / 33% | 61.1% / 33% | 6.9% / 50% | 4.92% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -229.6% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$9M |
| Free Cash Flow | -$9M |
| Total Debt | $3M |
| Current Ratio | 0.1 |
| Total Assets | $5M |
Price & Trading
| Last Close | $0.13 |
| 50-Day MA | $1.00 |
| 200-Day MA | $4.94 |
| Avg Volume | 1.8M |
| Beta | 0.2 |
|
52-Week Range
$0.09
| |
About Abpro Holdings, Inc. (ABPO)
Abpro Holdings, Inc., a biotechnology company, focuses on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets; and MultiMab, an engineering platform that provides the flexibility to combine antibody building blocks in different combinations and orientations to create fit for purpose novel full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 is developed for the treatment of HER2+ solid tumors, including breast and gastric cancers; and ABP-201, a TetraBi antibody format that simultaneously inhibit VEGF and ANG-2 for the treatment of vascular diseases of the eye, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for the treatment of hepatocellular carcinoma; and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for the treatment of gastric cancers. The company has strategic partnership with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Abpro Holdings, Inc. (ABPO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Abpro Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Abpro Holdings, Inc.'s debt ratio?
Abpro Holdings, Inc.'s debt ratio is 1124.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 71.4%.
What are Abpro Holdings, Inc.'s key financial metrics?
Abpro Holdings, Inc. has a market capitalization of $350,399, and revenue of $183,000.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.